Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Malignant Neoplasm

Interventions

DRUG: ponatinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

Sameek Roychowdhury